{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-228902","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-05-18T20:06:05+00:00","discovered_at":"2026-05-18T20:07:00.428959+00:00","generated_at":"2026-05-18T20:09:41.340643+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mirum issues $690M zero-coupon convertible notes due 2032; exchanges $237M of 2029 notes","bullets":["Issued $690M aggregate principal of 0.00% Convertible Senior Notes due 2032, including $90M option exercise.","Initial conversion price ~$138.94 per share, a 30% premium over $106.88 closing price on pricing date.","Concurrently exchanged ~$237.2M of existing 4.00% 2029 notes for $475M cash and ~3.22M shares.","Net proceeds ~$671.6M; remainder for general corporate purposes and potential acquisitions.","Notes mature June 1, 2032; redeemable after June 6, 2029 under stock price conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228902","json":"https://secwatch.observer/filing/0001193125-26-228902.json","markdown":"https://secwatch.observer/filing/0001193125-26-228902.md","text":"https://secwatch.observer/filing/0001193125-26-228902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/d113366d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T20:09:41.340643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad5f19bfa9cc8415f707eec1fb64820890675a76","claim":"Mirum Pharmaceuticals, Inc. incurred convertible notes of $690.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing June 1, 2032.","evidence_excerpt":"On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$690.0 million aggregate principal amount"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Rate","value":"0.00%"},{"label":"Maturity","value":"June 1, 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2b55a4045764a9b21573bc852e5fea25e5d6be58","claim":"Mirum Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $690.0 million (effective 2026-05-15).","evidence_excerpt":"On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million aggregate principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of May 15, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Value","value":"$690.0 million"},{"label":"Effective","value":"2026-05-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}